bpc-157 mode of action – No Proof Required! | Office for Science and Society BPC-157 ORAL - Beverly Hills

It has been shown to modulate gene expression in cancer cells, such as MCF7 breast cancer cells and PC3 prostate cancer cells

Some cited clinical trials are small

The evaluation determines the right starting point

The phase 3 TRIUMPH-4 data showed these rates at 9 mg and 12 mg doses respectively: Nausea: 38.1% and 43.2% (vs 10.7% placebo) Diarrhea: 34.7% and 33.1% (vs 13.4% placebo) Constipation: 21.8% and 25.0% (vs 8.7% placebo) Vomiting: 20.4% and 20.9% (vs placebo) These numbers are higher than cagrilintide monotherapy across the board

Andrew Huberman mentioned using the peptide for L5 vertebral compression pain, reporting pain elimination after just 2 injections

With 3 colors and 3 correctors, you can create the ideal shade for each client